title: Prolonged immunosuppressive effect and minimal immunogenicity from chimeric (CD25) monoclonal antibody SDZ CHI 621 in renal transplantation.
authors.affiliation: Sandoz Pharma Ltd., Basle, Switzerland.
authors.forename: J M
authors.initials: JM
authors.lastname: Kovarik
authors.forename: E
authors.initials: E
authors.lastname: Rawlings
authors.forename: P
authors.initials: P
authors.lastname: Sweny
authors.forename: O
authors.initials: O
authors.lastname: Fernando
authors.forename: R
authors.initials: R
authors.lastname: Moore
authors.forename: P J
authors.initials: PJ
authors.lastname: Griffin
authors.forename: P
authors.initials: P
authors.lastname: Fauchald
authors.forename: D
authors.initials: D
authors.lastname: Albrechtsen
authors.forename: G
authors.initials: G
authors.lastname: Sodal
authors.forename: K
authors.initials: K
authors.lastname: Nordal
authors.forename: P L
authors.initials: PL
authors.lastname: Amlot
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy; D007680:Kidney Neoplasms / Q000276:immunology*; D008297:Male; D051379:Mice; D008875:Middle Aged; D011446:Prospective Studies; D015375:Receptors, Interleukin-2 / Q000276:immunology; D011993:Recombinant Fusion Proteins / Q000009:adverse effects / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D015375:Receptors, Interleukin-2; D011993:Recombinant Fusion Proteins